97. 潰瘍性大腸炎 ［臨床試験数：2,269，薬物数：1,331（DrugBank：241），標的遺伝子数：114，標的パスウェイ数：181］
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|July 30, 2020||2/7/2020||Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories||3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis||Ulcerative Proctitis||Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator;Combination Product: Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator;Combination Product: Twice daily placebo suppository administered with Sephure applicator||Cristcot LLC||Cristcot HCA LLC||Recruiting||18 Years||N/A||All||618||Phase 3||United States|
|29/07/2020||29/07/2020||A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum.||A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum. - cessa||Ulcerative Colitis of the Rectum |
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;Level: HLT;Classification code 10027682;Term: Immune and associated conditions NEC;System Organ Class: 10021428 - Immune system disorders
MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;Level: HLGT;Classification code 10027665;Term: Immune disorders NEC;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
|Product Name: 90 mg hydrocortisone acetate suppository with Sephure suppository applicator|
INN or Proposed INN: HYDROCORTISONE ACETATE
|Cristcot HCA LLC||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|618||Phase 3||United States;Philippines;Hong Kong;Spain;Poland;Ukraine;Romania;Russian Federation;Germany;Italy;India|
|May 2017||19/2/2017||Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis||A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC)||Ulcerative Colitis, Unspecified||Drug: Mesalazine;Drug: hydrocortisone sodium succinate;Drug: Mesalazine with hydrocortisone sodium succinate||Xijing Hospital of Digestive Diseases||Shanghai Tongji Hospital, Tongji University School of Medicine;First Affiliated Hospital of Zhongshan Medical University||Recruiting||18 Years||70 Years||All||528||Phase 4||China|
|December 2016||21/4/2015||A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis||A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis||Ulcerative Colitis||Drug: Azathioprine;Drug: Infliximab;Drug: Prednisolone;Drug: Hydrocortisone||Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||NULL||Recruiting||18 Years||N/A||All||146||Phase 4||France|
|October 2008||8/12/2008||The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis||Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study||Inflammatory Bowel Disease;Ulcerative Colitis||Drug: Combination Oral Budesonide and Rectal Hydrocortisone||University of Maryland, Baltimore||NULL||Terminated||18 Years||N/A||All||1||Phase 2||United States|